TGA Gives Clear Signal To Zydus nod to conduct Phase II clinical study in patients with CAPS – Aus
Synopsis- Zydus announced today that it has received permission to initiate the Phase II (a) clinical study of its NLRP3 inhibitor “ZYIL1”…
Synopsis- Zydus announced today that it has received permission to initiate the Phase II (a) clinical study of its NLRP3 inhibitor “ZYIL1”…
KEYPOINTS: In this programme, DawaaDost will retail Metformin 1000 mg tablets from the top 10 pharmaceutical companies in the country. One in…
SUMMARY: ViiV Healthcare announces the European Commission Decision for Vocabria (Cabotegravir) and Rekambys (Rilpivirine) injections to be initiated with or without an…
SUMMARY: The U.S. Food and Drug Administration, the National Institutes of Health, 10 pharmaceutical companies and five non-profit organizations have partnered to…
Key Points – AION Labs, a first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges,…